Clinical Trials
Discover the future of medicine today. Yale Medicine currently offers 694 active clinical trials across our hospitals and care centers, providing our patients with early access to many of the world’s most advanced therapies. Yale Center for Clinical Investigation (YCCI) supports, coordinates, and oversees clinical trials, ensuring the safety of trial volunteers.
For more information about cancer-related trials, call us at 203-785-5702. For all other trials, call 877-978-8343.
8 Results
The Cancer of the Pancreas Screening-5 (CAPS5) Study
- Pancreatic Cancer
- Gender:All Genders
- Age:18 years and older
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma
- Pancreatic Cancer
PROgram to address psychosocial Support, clinical outcomes, and genomic insights for Patients with EaRly onset cancers
- Colorectal Cancer
- Sarcoma Cancers
- Stomach and Esophagus
- Kidney Cancer
- Head and Neck Cancers
- Liver Cancer
- Lung Cancer
- Gynecological Cancers
- Pancreatic Cancer
- Prostate Cancer
- Thyroid and Other Endocrine Cancers
- Breast Cancer
Pediatric Genomics Discovery Program (PGDP)
- Children's Health
- Genetics
- Gender:All Genders
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)
- Phase 1 Cancers
A Phase 1a/1b Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors
- Phase 1 Cancers
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors
- Phase 1 Cancers
YL211-INT-101-01: A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients with Advanced Solid Tumors [Advarra]
- Phase 1 Cancers